The ROC curves and AUC values of the diagnostic model. by Zhe Wu (582498)

Impact of changes in competitive strength of direct marketing channels on pharmaceutical pricing and profits. by Yan Wen (416285)

A summary of the included study characteristics. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

ROC curve and AUC value of all models. by Tiago de Oliveira Barreto (20485207)

“…As for Specificity (82.94%) and ROC-AUC (82.13%), the Multilayer Perceptron with SGD optimizer obtained the highest scores. …”

Column charts of WiAUC in therapy and control group at baseline and follow-up. by Felix L. Herr (21544362)

Feature importance and beeswarm plot determined by mean absolute SHAP values for the DeepSurv model. by Theophilus Gyedu Baidoo (21162511)

“…<p>(A) A comprehensive view of the influence each variable has on model predictions, with N Stage Status ranked on top (B) Bar plot of mean absolute SHAP values by decreasing order of importance</p>…”

Real-world mepolizumab treatment in patients with severe asthma decreased exacerbations, oral corticosteroid use, and healthcare resource utilization and costs over 4 years: a retr... by Wendy C. Moore (10682686)

“…This study evaluated the real-world impact of mepolizumab treatment in patients with severe asthma over a 4-year follow-up period.</p> <p>This was a retrospective cohort study of patients with asthma initiating mepolizumab (index date: first claim, November 2015–September 2019) using the Merative MarketScan Commercial and Medicare Databases. …”

Feature importance and beeswarm plot determined by mean absolute SHAP values for the random survival forest (RSF) model. by Theophilus Gyedu Baidoo (21162511)

“…(B) Bar plot of mean absolute SHAP values by decreasing order of importance.…”

Decrease in loss during the training process. by Muhammad Idrees (92773)

Daily number of adverse outcomes (bars) and area under the precision-recall curve (AUC-PRC) per day of the fullPIERS model. by Guiyou Yang (10259597)

Daily number of adverse outcomes (bars) and area under the precision-recall curve (AUC-PRC) per day of the PIERS-ML model. by Guiyou Yang (10259597)

Area under the curve (AUC) for external validation performance. by Junichi Kushioka (12236447)

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

<b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>" by Kira Shaw (18796168)

“…<p dir="ltr">The CSV file 'Eyreetal_DrainingVein_SourceData' contains the averaged time series traces and extracted metrics from individual experiments used across Figures 1-5 in the manuscript "Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins". The following acronyms included in the CSV file are defined as follows: Hbt is total hemoglobin, Art is artery region, DV is draining vein region, WV is whisker vein region, SEM is standard error mean, TS is time series, max peak is maximum peak, min peak is minima, AUC is area under the curve, WT is wild-type, AD is Alzheimer's disease, ATH is atherosclerosis and MIX is mixed AD/atherosclerosis. …”

Symbols and meanings. by Yan Wen (416285)

Naringenin decreases mitochondrial function. by Lauren A. Eanes (20995499)

AUC of various models to predict imeglimin efficacy for liver function evaluated by ROC curves. by Naruyoshi Gyoutoku (22537831)